Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
 Back to Details

Connection

Michael Birrer to Vision Disorders

This is a "connection" page, showing publications Michael Birrer has written about Vision Disorders.

 
Connection Strength
  
 
 
0.283
  
  1. Moore KN, Borghaei H, O'Malley DM, Jeong W, Seward SM, Bauer TM, Perez RP, Matulonis UA, Running KL, Zhang X, Ponte JF, Ruiz-Soto R, Birrer MJ. Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor a-targeting antibody-drug conjugate, in patients with solid tumors. Cancer. 2017 Aug 15; 123(16):3080-3087.
    View in: PubMed
    Score: 0.143
  2. Moore KN, Martin LP, O'Malley DM, Matulonis UA, Konner JA, Perez RP, Bauer TM, Ruiz-Soto R, Birrer MJ. Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study. J Clin Oncol. 2017 Apr 01; 35(10):1112-1118.
    View in: PubMed
    Score: 0.140
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.